What question did this study set out to answer?

The aim is to evaluate the effectiveness and safety of radiopharmaceuticals in patient-derived cancer models.

End-to-End Evaluation of Radiopharmaceuticals in Patient-Derived Models

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the effectiveness and safety of radiopharmaceuticals in patient-derived cancer models.
Developed PSMA-617 radiolabeled with 68Ga and 177Lu.
Conducted in vitro assays using 2D and 3D patient-derived models (PDXO, CDX).
Applied immunofluorescence to assess DNA damage in prostate cancer cells.
Utilized PET imaging for monitoring tumor response in vivo.
Monitored tumor growth and body weight in PDX models after radiopharmaceutical treatment.
Achieved >95% radiochemical purity of labeled PSMA-617.
Demonstrated differential tumor responses to treatment based on PSMA expression levels.
Supported findings with diagnostic PET imaging across models.

No takes yet. Share an insight, caveat, or question.

Demonstrates targeted radionuclide therapy efficacy in patient-derived models, indicating improved treatment personalization.

Liu et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark